THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Anjan Pradhan to Xenograft Model Antitumor Assays

This is a "connection" page, showing publications Anjan Pradhan has written about Xenograft Model Antitumor Assays.
  1. Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1?. Proc Natl Acad Sci U S A. 2021 05 25; 118(21).
    View in: PubMed
    Score: 0.174
  2. MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF. Proc Natl Acad Sci U S A. 2019 03 19; 116(12):5687-5692.
    View in: PubMed
    Score: 0.149
  3. Recombinant MDA-7/IL24 Suppresses Prostate Cancer Bone Metastasis through Downregulation of the Akt/Mcl-1 Pathway. Mol Cancer Ther. 2018 09; 17(9):1951-1960.
    View in: PubMed
    Score: 0.142
  4. Noninvasive therapy of brain cancer using a unique systemic delivery methodology with a cancer terminator virus. J Cell Physiol. 2024 Aug; 239(8):e31302.
    View in: PubMed
    Score: 0.054
  5. Suppression of Prostate Cancer Pathogenesis Using an MDA-9/Syntenin (SDCBP) PDZ1 Small-Molecule Inhibitor. Mol Cancer Ther. 2019 11; 18(11):1997-2007.
    View in: PubMed
    Score: 0.038
  6. Knockout of MDA-9/Syntenin (SDCBP) expression in the microenvironment dampens tumor-supporting inflammation and inhibits melanoma metastasis. Oncotarget. 2016 Jul 26; 7(30):46848-46861.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES